Summary
Gilead Sciences, Inc. reported strong financial performance for the third quarter and first nine months of 2013, with total revenues increasing by 15% and 14% year-over-year, respectively. This growth was primarily driven by a 15% increase in product sales, largely attributable to the antiviral franchise, which saw a 14% rise. The company also highlighted significant revenue growth in its cardiovascular products. Net income increased by 17% year-over-year for the third quarter, reflecting robust sales and effective cost management. Financially, Gilead Sciences maintained a healthy liquidity position with $2.76 billion in cash, cash equivalents, and marketable securities as of September 30, 2013. The company actively managed its debt, repaying a significant portion of its long-term obligations. Key strategic developments include the completion of the YM BioSciences acquisition, aimed at advancing its oncology pipeline with momelotinib. Furthermore, Gilead is progressing with its Hepatitis C (HCV) pipeline, with a New Drug Application (NDA) filed for sofosbuvir and positive outlooks from FDA advisory committees. Investors should note the ongoing patent litigation related to key antiviral products, which presents potential risks, although the company has settled some cases and is actively defending others.
Financial Highlights
53 data points| Revenue | $2.78B |
| Cost of Revenue | $681.87M |
| Gross Profit | $2.03B |
| R&D Expenses | $546.24M |
| SG&A Expenses | $406.86M |
| Operating Expenses | $1.63B |
| Operating Income | $1.15B |
| Interest Expense | $73.95M |
| Net Income | $789.00M |
| EPS (Basic) | $0.51 |
| EPS (Diluted) | $0.47 |
| Shares Outstanding (Basic) | 1.53B |
| Shares Outstanding (Diluted) | 1.69B |
Key Highlights
- 1Total revenues increased 15% year-over-year to $2.78 billion in Q3 2013, driven by strong product sales.
- 2Product sales grew 15% to $2.71 billion in Q3 2013, with the antiviral franchise showing a 14% increase.
- 3Net income attributable to Gilead increased 17% to $788.6 million in Q3 2013, resulting in diluted EPS of $0.47.
- 4The company completed the acquisition of YM BioSciences for $487.6 million, strengthening its oncology pipeline with momelotinib.
- 5Gilead filed an NDA for sofosbuvir for Hepatitis C treatment, with FDA advisory committees providing positive recommendations.
- 6Cash, cash equivalents, and marketable securities stood at $2.76 billion as of September 30, 2013, indicating a strong liquidity position.
- 7The company continued to manage its debt, with total long-term debt, net decreasing to $5.86 billion from $7.05 billion at the end of 2012.